Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/259238 |
Resumo: | Aims: Liraglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist used as an anti-hyperglycemic agent in type 2 diabetes treatment and recently approved for obesity management. Weight loss is attributed to appetite suppression, but therapy may also increase energy expenditure. To further investigate the effect of GLP-1 signaling in thermogenic fat, we assessed adipose tissue oxygen consumption and type 2 deiodinase (D2) activity in mice treated with liraglutide, both basally and after β3-adrenergic treatment. Methods: Male C57BL/6J mice were randomly assigned to receive liraglutide (400 μg/kg, n=12) or vehicle (n=12). After 16 days, mice in each group were co-treated with the selective β3-adrenergic agonist CL316,243 (1 mg/kg, n=6) or vehicle (n=6) for 5 days. Adipose tissue depots were assessed for gene and protein expression, oxygen consumption, and D2 activity. Results: Liraglutide increased interscapular brown adipose tissue (iBAT) oxygen consumption and enhanced β3-adrenergic-induced oxygen consumption in iBAT and inguinal white adipose tissue (ingWAT). These effects were accompanied by upregulation of UCP-1 protein levels in iBAT and ingWAT. Notably, liraglutide increased D2 activity without significantly upregulating its mRNA levels in iBAT and exhibited additive effects to β3-adrenergic stimulation in inducing D2 activity in ingWAT. Conclusions: Liraglutide exhibits additive effects to those of β3-adrenergic stimulation in thermogenic fat and increases D2 activity in BAT, implying that it may activate this adipose tissue depot by increasing intracellular thyroid activation, adding to the currently known mechanisms of GLP-1A-induced weight loss. |
id |
UFRGS-2_eaed64fa167cc0bb05e00d443e56beda |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/259238 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Oliveira, Fernanda Cerqueira Barroso deBauer, Eduarda JacintoRibeiro, Carolina MartinsPereira, Sidney AlcântaraBeserra, Bruna T. S.Wajner, Simone MagagninMaia, Ana Luiza SilvaNeves, Francisco de Assis RochaCoelho, Michella S.Amato, Angélica Amorim2023-06-21T03:31:26Z20221664-2392http://hdl.handle.net/10183/259238001168604Aims: Liraglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist used as an anti-hyperglycemic agent in type 2 diabetes treatment and recently approved for obesity management. Weight loss is attributed to appetite suppression, but therapy may also increase energy expenditure. To further investigate the effect of GLP-1 signaling in thermogenic fat, we assessed adipose tissue oxygen consumption and type 2 deiodinase (D2) activity in mice treated with liraglutide, both basally and after β3-adrenergic treatment. Methods: Male C57BL/6J mice were randomly assigned to receive liraglutide (400 μg/kg, n=12) or vehicle (n=12). After 16 days, mice in each group were co-treated with the selective β3-adrenergic agonist CL316,243 (1 mg/kg, n=6) or vehicle (n=6) for 5 days. Adipose tissue depots were assessed for gene and protein expression, oxygen consumption, and D2 activity. Results: Liraglutide increased interscapular brown adipose tissue (iBAT) oxygen consumption and enhanced β3-adrenergic-induced oxygen consumption in iBAT and inguinal white adipose tissue (ingWAT). These effects were accompanied by upregulation of UCP-1 protein levels in iBAT and ingWAT. Notably, liraglutide increased D2 activity without significantly upregulating its mRNA levels in iBAT and exhibited additive effects to β3-adrenergic stimulation in inducing D2 activity in ingWAT. Conclusions: Liraglutide exhibits additive effects to those of β3-adrenergic stimulation in thermogenic fat and increases D2 activity in BAT, implying that it may activate this adipose tissue depot by increasing intracellular thyroid activation, adding to the currently known mechanisms of GLP-1A-induced weight loss.application/pdfengFrontiers in endocrinology. Lausanne. Vol. 12 (Jan. 2022), artigo 803363, 11 p.Tecido adiposoAgonistas de receptores adrenérgicos beta 3Peptídeos semelhantes ao glucagonIodeto peroxidaseLiraglutidaGLP-1 receptor agonistAdipose tissueLiraglutideType 2 deiodinaseβ3-adrenergic stimulationLiraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissueEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001168604.pdf.txt001168604.pdf.txtExtracted Texttext/plain47196http://www.lume.ufrgs.br/bitstream/10183/259238/2/001168604.pdf.txtb1a9a341539670939deecb069163fdc4MD52ORIGINAL001168604.pdfTexto completo (inglês)application/pdf5371683http://www.lume.ufrgs.br/bitstream/10183/259238/1/001168604.pdf4a2c533e755675fb6393405e1ebeb7a1MD5110183/2592382023-06-22 03:31:02.790248oai:www.lume.ufrgs.br:10183/259238Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2023-06-22T06:31:02Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue |
title |
Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue |
spellingShingle |
Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue Oliveira, Fernanda Cerqueira Barroso de Tecido adiposo Agonistas de receptores adrenérgicos beta 3 Peptídeos semelhantes ao glucagon Iodeto peroxidase Liraglutida GLP-1 receptor agonist Adipose tissue Liraglutide Type 2 deiodinase β3-adrenergic stimulation |
title_short |
Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue |
title_full |
Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue |
title_fullStr |
Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue |
title_full_unstemmed |
Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue |
title_sort |
Liraglutide activates type 2 deiodinase and enhances β3-adrenergic-induced thermogenesis in mouse adipose tissue |
author |
Oliveira, Fernanda Cerqueira Barroso de |
author_facet |
Oliveira, Fernanda Cerqueira Barroso de Bauer, Eduarda Jacinto Ribeiro, Carolina Martins Pereira, Sidney Alcântara Beserra, Bruna T. S. Wajner, Simone Magagnin Maia, Ana Luiza Silva Neves, Francisco de Assis Rocha Coelho, Michella S. Amato, Angélica Amorim |
author_role |
author |
author2 |
Bauer, Eduarda Jacinto Ribeiro, Carolina Martins Pereira, Sidney Alcântara Beserra, Bruna T. S. Wajner, Simone Magagnin Maia, Ana Luiza Silva Neves, Francisco de Assis Rocha Coelho, Michella S. Amato, Angélica Amorim |
author2_role |
author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Oliveira, Fernanda Cerqueira Barroso de Bauer, Eduarda Jacinto Ribeiro, Carolina Martins Pereira, Sidney Alcântara Beserra, Bruna T. S. Wajner, Simone Magagnin Maia, Ana Luiza Silva Neves, Francisco de Assis Rocha Coelho, Michella S. Amato, Angélica Amorim |
dc.subject.por.fl_str_mv |
Tecido adiposo Agonistas de receptores adrenérgicos beta 3 Peptídeos semelhantes ao glucagon Iodeto peroxidase Liraglutida |
topic |
Tecido adiposo Agonistas de receptores adrenérgicos beta 3 Peptídeos semelhantes ao glucagon Iodeto peroxidase Liraglutida GLP-1 receptor agonist Adipose tissue Liraglutide Type 2 deiodinase β3-adrenergic stimulation |
dc.subject.eng.fl_str_mv |
GLP-1 receptor agonist Adipose tissue Liraglutide Type 2 deiodinase β3-adrenergic stimulation |
description |
Aims: Liraglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist used as an anti-hyperglycemic agent in type 2 diabetes treatment and recently approved for obesity management. Weight loss is attributed to appetite suppression, but therapy may also increase energy expenditure. To further investigate the effect of GLP-1 signaling in thermogenic fat, we assessed adipose tissue oxygen consumption and type 2 deiodinase (D2) activity in mice treated with liraglutide, both basally and after β3-adrenergic treatment. Methods: Male C57BL/6J mice were randomly assigned to receive liraglutide (400 μg/kg, n=12) or vehicle (n=12). After 16 days, mice in each group were co-treated with the selective β3-adrenergic agonist CL316,243 (1 mg/kg, n=6) or vehicle (n=6) for 5 days. Adipose tissue depots were assessed for gene and protein expression, oxygen consumption, and D2 activity. Results: Liraglutide increased interscapular brown adipose tissue (iBAT) oxygen consumption and enhanced β3-adrenergic-induced oxygen consumption in iBAT and inguinal white adipose tissue (ingWAT). These effects were accompanied by upregulation of UCP-1 protein levels in iBAT and ingWAT. Notably, liraglutide increased D2 activity without significantly upregulating its mRNA levels in iBAT and exhibited additive effects to β3-adrenergic stimulation in inducing D2 activity in ingWAT. Conclusions: Liraglutide exhibits additive effects to those of β3-adrenergic stimulation in thermogenic fat and increases D2 activity in BAT, implying that it may activate this adipose tissue depot by increasing intracellular thyroid activation, adding to the currently known mechanisms of GLP-1A-induced weight loss. |
publishDate |
2022 |
dc.date.issued.fl_str_mv |
2022 |
dc.date.accessioned.fl_str_mv |
2023-06-21T03:31:26Z |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/259238 |
dc.identifier.issn.pt_BR.fl_str_mv |
1664-2392 |
dc.identifier.nrb.pt_BR.fl_str_mv |
001168604 |
identifier_str_mv |
1664-2392 001168604 |
url |
http://hdl.handle.net/10183/259238 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Frontiers in endocrinology. Lausanne. Vol. 12 (Jan. 2022), artigo 803363, 11 p. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/259238/2/001168604.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/259238/1/001168604.pdf |
bitstream.checksum.fl_str_mv |
b1a9a341539670939deecb069163fdc4 4a2c533e755675fb6393405e1ebeb7a1 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1801225089392312320 |